118 related articles for article (PubMed ID: 28975114)
1. Activation of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway and response to everolimus in endocrine receptor-positive metastatic breast cancer - A retrospective pilot analysis and viewpoint.
Bajpai J; Ramaswamy A; Chandrasekharan A; Mishra S; Shet T; Gupta S; Badwe RA
South Asian J Cancer; 2017; 6(3):102-105. PubMed ID: 28975114
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
[TBL] [Abstract][Full Text] [Related]
3. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
[TBL] [Abstract][Full Text] [Related]
5. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
6. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
7. Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer.
Okazaki M; Horimoto Y; Tanabe M; Ichikawa Y; Tokuda E; Arakawa A; Kobayashi T; Saito M
Med Oncol; 2018 Mar; 35(4):48. PubMed ID: 29520681
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer.
Yi Z; Ma F
J Breast Cancer; 2017 Dec; 20(4):321-326. PubMed ID: 29285035
[TBL] [Abstract][Full Text] [Related]
9. Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.
Paplomata E; Zelnak A; Santa-Maria CA; Liu Y; Gogineni K; Li X; Moreno CS; Chen Z; Kaklamani V; O'Regan RM
Clin Breast Cancer; 2019 Jun; 19(3):188-196. PubMed ID: 30745109
[TBL] [Abstract][Full Text] [Related]
10. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
11. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
Yardley DA; Bosserman LD; O'Shaughnessy JA; Harwin WN; Morgan SK; Priego VM; Peacock NW; Bass JD; Burris HA; Hainsworth JD
Breast Cancer Res Treat; 2015 Nov; 154(1):89-97. PubMed ID: 26456573
[TBL] [Abstract][Full Text] [Related]
13. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
O'Shaughnessy J; Thaddeus Beck J; Royce M
Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
[TBL] [Abstract][Full Text] [Related]
14. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.
Ng VC; Johnson JJ; Cuellar S
J Oncol Pharm Pract; 2015 Dec; 21(6):433-42. PubMed ID: 24964967
[TBL] [Abstract][Full Text] [Related]
15. PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tekesin K; Emin Gunes M; Bayrak S; Akar E; Ozturk T; Altinay S; Tural D
J BUON; 2019; 24(5):1920-1926. PubMed ID: 31786856
[TBL] [Abstract][Full Text] [Related]
16. Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome.
Gong C; Xiao Q; Li Y; Gu Y; Zhang J; Wang L; Cao J; Tao Z; Zhao Y; Xie Y; Hu X; Wang B
Oncologist; 2021 Apr; 26(4):e580-e587. PubMed ID: 33191524
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites.
Li N; Hao Y; Xie J; Lin PL; Koo V; Ohashi E; Wu EQ
Clin Ther; 2016 Apr; 38(4):905-17. PubMed ID: 26947172
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
19. Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma.
Su R; Nan H; Guo H; Ruan Z; Jiang L; Song Y; Nan K
Hepatol Res; 2016 Dec; 46(13):1380-1391. PubMed ID: 26932478
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]